Investing

Canadian Small caps and Penny stocks

  • Last Updated:
  • May 11th, 2023 8:36 am
Tags:
None
Deal Addict
Jun 23, 2006
1782 posts
247 upvotes
Toronto
Realister wrote: Looking for a small cap or penny to throw 50k at. Looking to make small plays, in and out with 10% swings. Any suggestions?
ACB... with the 12-1 reverse split... stock dropped significantly...might be a good shot term play if everything works out with them.
Deal Addict
Dec 24, 2007
1993 posts
513 upvotes
Toronto
AGN is moving fast with today’s good news.

CEO and CSO are talking at lunch today, hopefully we close near .60 today.

Cheers and GLTA that are still holding.
Thread started in 2016 - 1927 fully gutted and renovated 2 storey detached home in the big T.O. - small projects still in progress.

RFD priceless!
Deal Fanatic
User avatar
May 2, 2006
8355 posts
2267 upvotes
GTA
Entered VS @ .22.

LITT is halted pending news.

GSI continues to look very strong. Gapped up this morning.

EDIT: LITT was apparently halted by SEC due to their previous COVID-19 related claims. Not good.
Last edited by izzyzz on Apr 14th, 2020 1:27 am, edited 1 time in total.
Deal Fanatic
User avatar
May 2, 2006
8355 posts
2267 upvotes
GTA
VS

Versus Partners with Kast to Expand Beyond Gaming Into Streaming Video

LOS ANGELES, April 14, 2020 (GLOBE NEWSWIRE) -- Versus Systems, Inc. ("Versus") (CSE:VS) (OTCQB:VRSSF) (FRANKFURT:BMVA) today announces an agreement with Kast to bring Versus’ proprietary in-app rewards technology to Kast’s successful watch party platform.

This is an important step for Versus in that Kast is the first non-gaming content partner to integrate the Versus rewards platform. Social streaming, watch parties and video are a part of what Business Wire estimates as a $250 Billion dollar global streaming market that is estimated to grow at 19% CAGR through 2024.

Kast is a real-time video sharing app with screen capture, voice, text, and video chat technology that makes it easy to connect with friends wherever they are in a watch party. Kast is the ultimate virtual living room solution for all your content needs. Kast has recently been featured in well-known media outlets like Wired, Mashable, The Next Web, The Evening Standard, NBC and more.

The two companies will work together to integrate real-world rewards into Kast’s watch party apps to increase engagement for hosts of watch parties, known as “Kasters,” and watch party spectators alike.

“Kast is a true pioneer in the watch party space,” said John O’Connell, Head of Business Development for Versus Systems. “We are excited to bring our in-game reward technologies to their apps, creators and spectators later this year.”

Justin Weissberg, Co-founder and President of Kast commented: “Versus brings real, tangible rewards to their partners’ growing audiences. We are excited to bring our community rewards they can experience with their Kast friends and family.”
Deal Fanatic
User avatar
May 2, 2006
8355 posts
2267 upvotes
GTA
Added more VS @ .215 at open. Idiots selling here but thank you. lol
Deal Fanatic
User avatar
May 2, 2006
8355 posts
2267 upvotes
GTA
This is also interesting with regards to IPA...



Deal Addict
Nov 14, 2006
3149 posts
1952 upvotes
GTA
MWM running, saw it too late so not going to chase at this point.
Newbie
Sep 26, 2016
9 posts
1 upvote
Thoughts on Datameterex? They're kits worked well in South Korea and they're currently in the process of getting approved by the FDA/CDC and Health Canada. Kits provide results in 15-20 minutes and are said to be 99.9% accurate.
Deal Fanatic
User avatar
May 2, 2006
8355 posts
2267 upvotes
GTA
gdhundal wrote: Thoughts on Datameterex? They're kits worked well in South Korea and they're currently in the process of getting approved by the FDA/CDC and Health Canada. Kits provide results in 15-20 minutes and are said to be 99.9% accurate.
I got some at .12 on pullback today.

Generally, I'd approach this one with caution and a stop loss. The company is known for promo driven sp rise, then fall. Quite diluted as well. Haven't seen this much volume on any stock in recent history though so it creates some nice opportunities if you play the volatility right.
Deal Fanatic
User avatar
May 2, 2006
8355 posts
2267 upvotes
GTA
I don't think revised NR had anything with today's drop. It went up way too fast and got extremely overbought. This type of setup always invites short sellers. Money is made both ways.

No reason to believe they can't get it approved but this is all spec driven right now because we don't know how much DM will be making from selling those kits. I do not plan on holding long-term.
Deal Fanatic
User avatar
May 2, 2006
8355 posts
2267 upvotes
GTA
Sold DM @ .14 (.12 avg).

@jimgiggles is right. These guys are sketchy. Play accordingly.

Also sold NSP @ .035 (.03 avg). Not particularly happy about PP at current levels. Could have done better by selling earlier but decent profit.
Last edited by izzyzz on Apr 20th, 2020 12:51 pm, edited 2 times in total.
Sr. Member
User avatar
Jul 23, 2006
614 posts
93 upvotes
Toronto
I removed earlier post about $DM.. Didn't want to get flamed with all the momentum on that stock..

Stage Zero Life Sciences out of Markham looks very promising....

$SZLS had a major news release today and it's sitting at about $.085 at the moment.. I got in at $.065 and holding tight.

https://twitter.com/stagezerols?lang=en

StageZero Life Sciences Initiates Testing for COVID-19 In the USA
T.SZLS | 4 hours ago
TORONTO, ON / ACCESSWIRE / April 20, 2020 / StageZero Life Sciences, Ltd (TSX:SZLS) ("StageZero" or the "Company") announced today that it is initiating testing for the SARS-CoV-2 virus from its CLIA-certified high complexity lab in Richmond, Virginia. The Company will offer both the PCR-based nucleic acid tests as well qualitative antibody testing. Quantitative antibody testing will be added once fully validated and approved.

The Company is first directing its testing to healthcare groups and frontline workers, which will include employers of frontline workers. As capacity grows, testing will be offered to physician groups with established patient relationships.

The PCR test:

PCR tests help determine if a patient has an active infection. StageZero is using Thermo Fisher Scientific's TaqPath RT-PCR Covid-19 kit to test for the SARS-CoV-2 virus. The kit has an EUA clearance and StageZero will operate under this authorization. The Company routinely uses Thermo Fisher Scientific equipment and procedures to conduct its RT-PCR mRNA analyses for its cancer screening tests, and is completing validation of the Covid-19 assay. This will be filed with the FDA this week which will allow testing to begin.

Qualitative antibody test:

Antibody tests can aid in the diagnosis of patients with suspected SARS-CoV-2 virus infection in conjunction with clinical presentation and the results of other laboratory tests. Antibody tests help determine if a patient has already been infected with the virus and is producing antibodies. StageZero is partnered with BTNX Inc. and will offer qualitative antibody testing using BTNX's Rapid Response COVID-19 IgG/IgM Test. The assays test for the presence of IgM and IgG and have a validated specificity of 99%, the key benchmark for these tests. On March 16, 2020 BTNX submitted under Section IV.D of the FDA's Policy for Diagnostic Tests for Coronavirus Disease-2019 and is listed on the FDA site. Subsequently, they submitted the kits to the New York State Department of Health for evaluation and confirmation of their results and are presently submitting an EUA to the FDA for approval.

StageZero will initially offer the BTNX Rapid Response test under Section IV.D of the FDA's Policy for Diagnostic Tests for Coronavirus Disease-2019 while awaiting EUA approval. FDA, CLIA and CAP guidelines lay out how the testing is to be conducted at this time:

The tests must be conducted within a CLIA-certified high complexity lab.
The test must be performed on a venous blood sample collected by a certified healthcare professional.
The tests need an authorized test requisition.
The results must be reported daily to the relevant State and Federal authorities under the signature of the lab.
"This is a highly coordinated effort to deliver COVID-19 testing as correctly and accurately as possible," said James Howard-Tripp, Chairman and CEO of StageZero Life Sciences. "In recent weeks there have been growing backlogs of patient samples being held up for testing due to high demand and limited capacity. These partnerships will ease some of that backlog".

COVID-19 Testing for Frontline Workers

StageZero Life Sciences will initially be offering SARS-CoV-2 virus testing to employers and healthcare workers serving on the frontlines. This will be expanded to physician groups with established patient relationships as testing capacity increases. Capacity is anticipated to ramp-up fairly quickly.

Telehealth a Critical Component of Testing to Reach Employees and Patients

StageZero Life Sciences has been offering testing via its own telehealth platform for well over a year. StageZero's Telehealth Platform allows physicians to initiate an order for blood tests for prostate, colorectal or breast cancer. Once authorized, the test requisitions are sent to a lab partner or our proprietary network of mobile phlebotomists who can perform blood draws in a patient's home.

"The telehealth model which has been thrust upon the country in recent weeks is something StageZero has been preparing for for well over a year," said Howard-Tripp. "Now, because of advanced planning, we are uniquely positioned to be able to get to "socially distanced" employees and patients to offer COVID-19 testing. We are, however, first and foremost a Cancer diagnostic company and will remain focused there. For now though, we are very pleased to be able to help."

About StageZero Life Sciences, Ltd.

StageZero Life Sciences is dedicated to the early detection of cancer and multiple disease states through whole blood. Aristotle®, our next generation test, is a panel for simultaneously screening for 10 discrete cancers from a single sample of blood with high sensitivity and specificity for each cancer. Aristotle is built on our proven and proprietary Sentinel Principle Technology Platform which has been validated on 10,000 patients and used to develop the first liquid biopsy for Colorectal Cancer, with further validation currently underway. In addition to building a pipeline of products for early cancer detection, the Company operates a CAP accredited and CLIA certified reference laboratory based in Richmond, Virginia that offers the ColonSentry® test as well as licensed biomarker tests for breast and prostate cancers. To learn more visit www.stagezerolifesciences.com.

Forward-Looking Statements

This press release contains forward-looking statements identified by words such as "expects", "will" and similar expressions, which reflect the Company's current expectations regarding future events. The forward-looking statements involve risks and uncertainties that could cause the Company's actual events to differ materially from those projected herein. Investors should consult the Company's ongoing quarterly filings and annual reports for additional information on risks and uncertainties relating to these forward-looking statements. The reader is cautioned not to rely on these forward-looking statements. The Company disclaims any obligation to update these forward-looking statements, except as required by law.

Company Contacts:

James R. Howard-Tripp
Chairman & CEO
jht@stagezerols.com
Tel: 1-855-420-7140 Ext. 1

Rebecca Greco
Investor Relations
rgreco@stagezerols.com
Tel: 1-855-420-7140 Ext. 1838

SOURCE: StageZero Life Sciences Ltd



View source version on accesswire.com:
https://www.accesswire.com/585873/Stage ... In-the-USA


ACCESSWIRE
April 20, 2020 - 5:00 AM PDT

Top

Thread Information

There is currently 1 user viewing this thread. (0 members and 1 guest)